Alnylam Pharmaceuticals – Amyloidosis, Hereditary

Submitted By:

Published Date:

January 25, 2020

The purpose of this study is to provide expanded access of patisiran to patients with
hereditary transthyretin-mediated amyloidosis (hATTR).

Rare Disease:

Osteogenesis imperfecta